EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sperm-Associated Antigen 5 Knockout Reduces Doxorubicin and Docetaxel Resistance in Triple-Negative Breast Cancer MDA-MB-231 and BT549 Cells

Ji He iD, Jiawei Li, Yanbiao Liu, Yan Li iD

Cancers · 24.03.2024 · 16 (7) · 1269

DOI: 10.3390/cancers16071269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 24.03.2024. Verfasst von Ji He und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Science, Auckland University of Technology, Auckland 1010, New Zealand. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Health and Environmental Science (Auckland University of Technology, NZ), Faculty of Health and Environmental Science (Auckland University of Technology, NZ) Research and Development Fund 2022.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sperm-associated antigen 5 (SPAG5), also known as Astrin, was previously demonstrated as a biomarker for cellular resistance to major breast cancer therapies, including chemo-, endocrine- and targeted therapy. However, the contribution of SPAG5 to anthracycline- and taxane-based chemotherapy in triple-negative breast cancer (TNBC) remains controversial. In the present study, the SPAG5 knockout cell model was established by using clustered regularly interspaced palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) system in MDA-MB-231 and BT549 TNBC cell lines. The knockout of SPAG5 was confirmed on both gene and protein levels using genomic PCR, DNA sequencing and western blotting. The functional loss of SPAG5 was determined by colony-formation assay. SPAG5-regulated doxorubicin- and docetaxel-resistance was assessed by MTT and apoptosis assays. The results indicated that all the SPAG5 knockout MDA-MB-231 and BT549 clones were biallelic, where one allele was replaced by the donor template, and the other allele had the same “T” insertion (indel) adjacent to the cutting sites of gRNAs at the exon 1 boundary, irrespective of the gRNAs and cell lines. The locus of indel interrupted the SPAG5 transcription by damaging the GT-AG mRNA processing rule. Deletion of SPAG5 decreased clonogenicity in both MDA-MB-231 and BT549 cells. SPAG5 was able to regulate the resistance and the drug-induced apoptosis of both doxorubicin and docetaxel. In conclusion, recombinant plasmid-based CRISPR-Cas9 technology can be used to delete the SPAG5 gene in the TNBC cell lines. SPAG5 has an important role in regulating cell proliferation and doxorubicin- and docetaxel-resistance in MDA-MB-231 and BT549 cells.

Schlagwörter

Stichwörter der Autor:innen

AstrinCRISPR-Cas9SPAG5docetaxeldoxorubicinknockouttriple-negative breast cancer

Autor:innen und Institutionen

  • School of Science, Auckland University of Technology, Auckland 1010, New Zealand.
  • Department of Food and Agriculture Technology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing 314006, China.
  • General Medicine Department, Shenzhen Longhua District Central Hospital, Shenzhen 518110, China.

ORCID-Profile: Ji He, Yan Li

Förderung

  • Faculty of Health and Environmental Science (Auckland University of Technology, NZ)
  • Faculty of Health and Environmental Science (Auckland University of Technology, NZ) Research and Development Fund 2022

Zitieren

APA

He, J., Li, J., Liu, Y., & Li, Y. (2024). Sperm-Associated Antigen 5 Knockout Reduces Doxorubicin and Docetaxel Resistance in Triple-Negative Breast Cancer MDA-MB-231 and BT549 Cells. Cancers, 16(7), 1269. https://doi.org/10.3390/cancers16071269

Vancouver

He J, Li J, Liu Y, Li Y. Sperm-Associated Antigen 5 Knockout Reduces Doxorubicin and Docetaxel Resistance in Triple-Negative Breast Cancer MDA-MB-231 and BT549 Cells. Cancers. 2024;16(7):1269. doi:10.3390/cancers16071269

BibTeX
@article{He2024,
  author = {He, Ji and Li, Jiawei and Liu, Yanbiao and Li, Yan},
  title = {Sperm-Associated Antigen 5 Knockout Reduces Doxorubicin and Docetaxel Resistance in Triple-Negative Breast Cancer MDA-MB-231 and BT549 Cells},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {7},
  pages = {1269},
  doi = {10.3390/cancers16071269}
}
Kostenlos starten →